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74 Gy without interruption and without missing any doses of q2wk B. 
Two had Gr 3 esophagitis. Only 2 of 5 from Cohort I have started (and 
completed) consolidation BEr (2 had persisitent Gr 3 esophagitis and 1 
early death due to disease progression). In Cohort II, 3 of 5 have com-
pleted I + C therapy (all doses of B were delivered during C therapy; 2 
are currently under treatment).
Conclusions: Preliminarily, we conclude that 1) Incorporation of B 
into this treatment paradigm is safe, 2) Esophagitis remains the primary 
toxicity and appeared to be unusually persistent in our initial cohort, 3) 
Accrual to Cohort III is ongoing.
PD4-1-3 Combined Modality Therapy in NSCLC, Tue, 16:00 - 17:30
How to improve loco-regional control in stage IIIa-b NSCLC? 
Results of a three-armed randomized trial from the Swedish Lung 
Cancer Study Group
Nyman, Jan1 Wagenius, Gunnar2 Friesland, Signe3 Seke, Mihalj4 
Sederholm, Christer5 Lödén, Brita6 Thaning, Lars7 Bergström, Stefan8 
Hallqvist, Andreas1 
1 Department of Oncology, Sahlgrenska University Hospital, Gothen-
burg, Sweden 2 Department of Oncology, Uppsala University Hospital, 
Uppsala, Sweden 3 Department of Oncology, Karolinska University 
Hospital, Stockholm, Sweden 4 Department of Oncology, University 
Hospital MAS, Malmö, Sweden 5 Department of Respiratory Medicine, 
Linköping University Hospital, Linköping, Sweden 6 Department of On-
cology, Central Hospital, Karlstad, Sweden 7 Department of Respirato-
ry Medecin, Örebro University Hospital, Örebro, Sweden 8 Department 
of Oncology, Gävle Hospital, Gävle, Sweden 
Background: Induction chemotherapy and radiotherapy is the treat-
ment base for locally advanced non-small cell lung cancer (NSCLC). 
However, both loco-regional and distant failure is frequent. Attempts to 
improve the loco-regional control were made in three separate phase II 
studies in Swedish University Hospitals, where accelerated radiother-
apy or concomitant daily or weekly chemotherapy with conventional 
radiotherapy were tested. Comparatively good results from these stud-
ies lead to this national randomized phase II study, the RAKET-study, 
where the different concepts were investigated on a wider basis for 
further phase III studies. 
Methods: Inoperable stage III non-small cell lung cancer patients in 
good performance status (PS<2) were equally randomized to either of 
three arms A, B or C in eight institutions. All arms started with two 
cycles of induction chemotherapy: Paclitaxel 200 mg/m2 and carbo-
platin AUC6. Arm A: A third identical cycle was given concomitant 
with start of accelerated radiotherapy, 1.7 Gy BID to 64.6 Gy in 4.5 
weeks. Arm B consisted of daily concomitant paclitaxel 12 mg/m2 with 
conventionally fractionated radiotherapy: 2 Gy daily to 60 Gy in 6 
weeks. Arm C: Weekly concomitant paclitaxel 60 mg/m2 and identical 
radiotherapy to 60 Gy. Primary endpoint: TTP, Secondary: OS, toxicity, 
QL and relapse pattern.
Results: Between June 2002 and May 2005 152 patients were ran-
domized and 148 evaluable: 76 men and 72 women, median age 62 
years (43-78), 55% had Performance Status 0 and 45% PS 1. Mean 
pretreatment pulmonary function: FEV1:2.1 L (0.8-4.5). Thirty-four 
percent had stage IIIa and 66% IIIb. Histology: Adenocarcinoma 48%, 
squamous cell carcinoma 32% and 20% non-small cell carcinoma. The 
three arms were well balanced. 
Median time to progression: 8.9, 10.3 and 9.1 moths for arm A, B and 
C, respectively. Median survival: 17.7, 17.8 and 20.6 months for A, B 
and C. Two-year overall survival: 41%, 43% and 45% respectively for 
A, B and C.
Conclusions: Treatment results are quite equal by intensifying the 
loco-regional treatment either by accelerated fractionated radiotherapy 
or daily or weekly concomitant chemo-radiotherapy. Toxicity and qual-
ity of life data, that soon will be completed and reported at the meeting, 
will be of great importance for further decisions. 
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Background: The recommended treatment in inoperable stage III 
non-small cell lung cancer (NSCLC) is concurrent chemoradiotherapy 
(CCRT). Recent phase II trial for the consolidation chemotherapy with 
docetaxel after CCRT gave promising data, but the survival beneﬁt of 
consolidation chemotherapy after CCRT has not been determined yet. 
This study is multinational, multicenter, phase III randomized trial to 
determine the efﬁcacy of consolidation chemotherapy with docetaxel 
and cisplatin after completing CCRT with the same chemotherapeutic 
agents in stage III inoperable NSCLC. Here we report the preliminary 
data for feasibility and safety analysis of this trial.
Methods: Patients with inoperable stage III NSCLC were eligible. N2 
or N3 disease was conﬁrmed by PET or pathology. Eligible patients 
were randomized to either observation or consolidation chemotherapy 
arm. During CCRT, docetaxel (20 mg/m2) and cisplatin (20 mg/m2) 
were administered every week for 6 times and a total dose of 66 Gy of 
thoracic radiation therapy was given in 33 fractions. In consolidation 
arm, the patients were further treated for 3 cycles with docetaxel and 
cisplatin (35 mg/m2 on day 1 and 8, every 3 weeks).
Results: Eighty one patients were enrolled from May 2005 to early 
January 2007. Seventy eight patients were evaluable. Thirty six patients 
were randomized to CCRT alone and 42 patients to CCRT with con-
solidation. Patients’ characteristics were similar in both arms. CCRT 
was generally well tolerated. During CCRT, frequent non-hematologic 
toxicities of all grades were anorexia(55%), nausea(60%), asthe-
nia(29%), alopecia(37%), and esophagitis(83%). Grade 3-4 toxicities 
were rare and radiation-associated esophagitis was observed in 10.4% 
of patients. Hematololgic toxicities during CCRT were mild and grade 
3-4 toxicities were observed in 4 patients The toxicities, which led 
to death, occurred in 4 patients and all those toxicities were probably 
related to CCRT. Eighty percent of patients who were randomized to 
consolidation arm received consolidation chemotherapy and 78% of 
patients who started consolidation chemotherapy completed at least 
